Press coverage about Heron Therapeutics (NASDAQ:HRTX) has been trending somewhat positive on Wednesday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Heron Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.5577142696258 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

A number of equities analysts recently weighed in on HRTX shares. Cowen and Company restated a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a report on Friday, May 26th. ValuEngine upgraded shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Heron Therapeutics in a research note on Monday, June 26th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Wednesday, July 12th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $26.00 target price on shares of Heron Therapeutics in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. Heron Therapeutics currently has an average rating of “Buy” and an average price target of $29.25.

Shares of Heron Therapeutics (HRTX) opened at 15.05 on Wednesday. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $20.85. The stock’s market capitalization is $814.78 million. The firm’s 50-day moving average is $16.09 and its 200-day moving average is $14.95.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. Analysts forecast that Heron Therapeutics will post ($3.51) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/09/13/heron-therapeutics-hrtx-receives-news-impact-score-of-0-13.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Insider Buying and Selling by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.